{
    "nctId": "NCT02905916",
    "briefTitle": "The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy",
    "officialTitle": "N/A",
    "overallStatus": "UNKNOWN",
    "conditions": "Mammary Cancer, Lymphoma, Bone Tumour, Gynecological Tumors",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 217,
    "primaryOutcomeMeasure": "Incidence of febrile neutropenia (FN)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with age between 18 and 70 years.\n2. Breast cancer, lymphoma, bone tumor or Gynecologic tumor patients.\n3. With multi-cycle chemotherapy.\n4. With III/IV degree neutropenia after the last cycle of chemotherapy and plans to use the same regimen in the subsequent cycles.FN risk of the chemotherapy regimens is \u226520%\uff0cor 10%\u2264FN risk\\<20% and has high risk factors associated with FN.\n5. KPS score\u2265 70.\n6. Expected to survive more than 3 months.\n7. No hematologic system disease and ANC\u22651.5\u00d710E9/L, PKT\u226580\u00d710E9/L, Hb\u2265 75g/L, WBC\u22653\u00d710E9/L, and no bleeding tendency.\n8. Written informed consent are acquired. -\n\nExclusion Criteria:\n\n1. With infection or systemic antibiotic therapy 72h before chemotherapy.\n2. With any abnormal hematopoietic function.\n3. Received transplantation within 3 months.\n4. Suffered from other malignant tumor or brain metastases.\n5. TBIL, ALT,AST \\> 2.5\u00d7ULN; if it were caused by liver metastases, TBIL, ALT,AST \\>5\u00d7ULN.\n6. Cr \\>1.5 \u00d7ULN.\n7. Sensitive to the product or other genetically engineered biological products from Escherichia coli strains.\n8. Mental or nervous system disorders.\n9. Refused to accept contraceptive measures.\n10. Other situations that investigators consider as contra-indication for this study.\n\n    -",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}